Pa­trizia Cavaz­zoni named per­ma­nent di­rec­tor of CDER, adding to ques­tions around where Wood­cock will end up

Pa­trizia Cavaz­zoni on Mon­day be­came the per­ma­nent di­rec­tor of the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search, which puts to rest the idea that Janet Wood­cock, Cavaz­zoni’s pre­de­ces­sor, might re­turn to lead CDER if she isn’t made per­ma­nent com­mis­sion­er.

Wood­cock, who’s cur­rent­ly serv­ing as act­ing com­mis­sion­er and prin­ci­pal med­ical ad­vi­sor to the com­mis­sion­er, a po­si­tion she was de­tailed to last year, may not make the move to per­ma­nent com­mis­sion­er be­cause of lin­ger­ing ques­tions from Sen­ate De­moc­rats. She pre­vi­ous­ly served as di­rec­tor of CDER since 1994. Cavaz­zoni took over as act­ing di­rec­tor of CDER when Wood­cock moved over to Op­er­a­tion Warp Speed to run the ther­a­peu­tics side of the Trump-era pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER